CJC-1295
Research-use contextResearch-use peptide · also: cjc1295, cjc 1295
A synthetic growth-hormone-releasing hormone (GHRH) analog sold as a research-use product; not FDA-approved.
People commonly track it for
Most often logged alongside other growth-hormone-secretagogue peptides in a sleep / recovery / body-composition context (user intent, not a proven effect).
Evidence summary
Limited clinical data. The FDA has noted reported adverse events (increased heart rate, systemic vasodilatory reaction).
Regulation & source status
Not FDA-approved. On the FDA Category-2 page under 'nominated but withdrawn' (not approval); it is not on the July 2026 PCAC agenda.
Route considerations
Commonly discussed as an injectable in community settings. We don't provide route, preparation, or technique guidance — that's a clinician/pharmacist conversation.
Storage considerations
Often sold as a powder for reconstitution; unregulated products have no verified storage or stability data. Storage specifics belong to a pharmacist, not this profile.
Interaction & context review
Because human data is limited, interactions aren't well characterized. If you track it alongside other items or medications, review the full list with a clinician or pharmacist.
Sport / duty status
Prohibited in sport — WADA S2 names CJC-1295 among growth-hormone-releasing factors.
Track this item
You can log this as a custom peptide / medication-context item — record your own source status, route, storage note, and a schedule, and include it in an export for your clinician. StackWise doesn't add a dose.
Track this itemPeptide safety & source review
Sources
Source reviewed: 2026-07-23.